RankingsPricing
  1. US-listed companies
  2. Viking Therapeutics, Inc.
  3. Financials
  4. Operating income

Viking Therapeutics, Inc.VKTX

Market cap
$4B
P/E ratio
SummaryFinancials
Period EndOperating income (Million USD)YoY (%)
Dec 31, 2024-151+49.68%
Dec 31, 2023-101+43.31%
Dec 31, 2022-70+26.35%
Dec 31, 2021-56+30.52%
Dec 31, 2020-43+30.52%
Dec 31, 2019-33+24.95%
Dec 31, 2018-26+37.18%
Dec 31, 2017-19+37.72%
Dec 31, 2016-14+15.43%
Dec 31, 2015-12

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)